Della Terra Pharmaceuticals

Della Terra Pharmaceuticals is a biotechnology company focused on the development of psychedelic-inspired medicines for the treatment of neurological and mental health disorders. The company specializes in the development of psilocin-based compounds and delivery systems aimed at addressing conditions such as Traumatic Brain Injury (TBI) and Post-Traumatic Stress Disorder (PTSD). In 2021, Della Terra was acquired by Lobe Sciences, integrating its research into Lobe's broader portfolio of psychedelic therapeutics. Their approach often involves combining psychedelic compounds with other agents, such as N-acetylcysteine (NAC), to enhance therapeutic outcomes. The company's lead programs are designed to provide the neuro-restorative benefits of psychedelics while minimizing hallucinogenic side effects.